NASDAQ:BIOL BIOLASE Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BIOLASE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $4.41 -0.16 (-3.50%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$4.41▼$4.9450-Day Range$3.42▼$115.0052-Week Range$3.30▼$23.49Volume35,459 shsAverage Volume32,414 shsMarket Capitalization$27.25 millionP/E RatioN/ADividend YieldN/APrice Target$41.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BIOLASE MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside841.0% Upside$41.50 Price TargetShort InterestHealthy3.95% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.32Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.53 out of 5 starsMedical Sector1002nd out of 1,433 stocksDental Equipment & Supplies Industry5th out of 6 stocks 3.5 Analyst's Opinion Consensus RatingBIOLASE has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.50, BIOLASE has a forecasted upside of 841.0% from its current price of $4.41.Amount of Analyst CoverageBIOLASE has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.95% of the float of BIOLASE has been sold short.Short Interest Ratio / Days to CoverBIOLASE has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in BIOLASE has recently decreased by 14.74%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBIOLASE does not currently pay a dividend.Dividend GrowthBIOLASE does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BIOL. Previous Next 2.4 News and Social Media Coverage News SentimentBIOLASE has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for BIOLASE this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for BIOL on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.MarketBeat Follows7 people have added BIOLASE to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BIOLASE insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.10% of the stock of BIOLASE is held by insiders.Percentage Held by InstitutionsOnly 11.38% of the stock of BIOLASE is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of BIOLASE is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BIOLASE is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBIOLASE has a P/B Ratio of 1.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BIOL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter. Email Address About BIOLASE (NASDAQ:BIOL) StockBIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, pain therapy, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.Read More BIOL Stock News HeadlinesJuly 7, 2022 | finance.yahoo.comBIOLASE ANNOUNCES PROMOTIONS OF KEY TEAM MEMBERSJuly 6, 2022 | americanbankingnews.comBIOLASE (NASDAQ:BIOL) Now Covered by StockNews.comJuly 1, 2022 | seekingalpha.comBIOLASE amends senior secured term loan with SWK Funding - Seeking AlphaJune 26, 2022 | americanbankingnews.comBIOLASE (NASDAQ:BIOL) Coverage Initiated by Analysts at StockNews.comJune 19, 2022 | americanbankingnews.comBIOLASE (NASDAQ:BIOL) Now Covered by Analysts at StockNews.comJune 13, 2022 | finance.yahoo.comBIOLASE ANNOUNCES ADVANCING DENTISTRY PODCASTJune 9, 2022 | finance.yahoo.comBIOLASE ANNOUNCES INAUGURAL CLINICAL EXCELLENCE FORUMJune 6, 2022 | finance.yahoo.comBIOLASE SIGNS LEASE TO EXPAND TRAINING AND EDUCATION INITIATIVESJune 1, 2022 | finance.yahoo.comBIOLASE CREATES FIRST-OF-ITS-KIND CLINICAL INTEGRATION TEAMMay 24, 2022 | finance.yahoo.comBIOLASE CEO SHARES VISION FOR KINDLER, GENTLER DENTISTRY WITH CUSTOMERS AROUND THE WORLDMay 20, 2022 | benzinga.comLake Street Initiates Coverage On Biolase with Buy Rating, Announces Price Target of $12 - Benzinga - BenzingaMay 16, 2022 | streetinsider.comBiolase (BIOL) Regains Nasdaq Compliance - StreetInsider.comMay 16, 2022 | finance.yahoo.comBIOLASE TO PARTICIPATE IN THE SPRING INTO ACTION BEST IDEAS VIRTUAL INVESTOR CONFERENCE MAY 17-20, 2022 - Yahoo FinanceMay 16, 2022 | finance.yahoo.comBIOLASE TO PARTICIPATE IN THE SPRING INTO ACTION BEST IDEAS VIRTUAL INVESTOR CONFERENCE MAY 17-20, 2022May 16, 2022 | finance.yahoo.comTherapeutic Dental Equipment Global Market Report 2022 - Yahoo FinanceMay 13, 2022 | finance.yahoo.comBIOLASE MAINTAINS GROWTH MOMENTUM AS FIRST QUARTER REVENUE INCREASED 25% YEAR OVER YEARMay 11, 2022 | benzinga.comEarnings Preview For Biolase - Benzinga - BenzingaMay 9, 2022 | finance.yahoo.comBIOLASE STRENGTHENS ITS BOARD OF DIRECTORS WITH ADDITION OF SEASONED HEALTHCARE EXECUTIVEApril 29, 2022 | benzinga.comThinking about buying stock in Biolase, GTY Technology, Redbox, KE Holdings, or Kingsoft Cloud? - BenzingaApril 29, 2022 | finance.yahoo.comBIOLASE ANNOUNCES 1-FOR-25 REVERSE STOCK SPLIT - Yahoo FinanceApril 29, 2022 | benzinga.comBiolase shares are trading lower after the company announced a 1-for-25 reverse stock split effective Apr - BenzingaApril 28, 2022 | finance.yahoo.comBIOLASE ANNOUNCES 1-FOR-25 REVERSE STOCK SPLITApril 11, 2022 | businesswire.comGlobal Medical Laser System Market Research Report to 2027 - Featuring Alcon Laboratories, Biolase and Lumenis Among Others - ResearchAndMarkets.com - Business WireMarch 28, 2022 | finance.yahoo.comGlobal Medical Lasers Market is estimated close to $3.5 Billion (2020). Market segments are growing at a CAGR from 8-12% through 2020-2025 - Yahoo FinanceMarch 23, 2022 | finance.yahoo.comBIOLASE TO PARTICIPATE IN MAXIM GROUP'S 2022 VIRTUAL GROWTH CONFERENCE HOSTED BY M-VEST ON MARCH 28TH - 30TH - Yahoo FinanceSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Dental equipment & supplies Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BIOL Previous SymbolNASDAQ:BLTI CUSIPN/A CIK811240 Webwww.biolase.com Phone(949) 361-1200Fax949-273-6677Employees158Year FoundedN/ACompany Calendar Last Earnings5/12/2022Today7/07/2022Next Earnings (Estimated)8/11/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$41.50 High Stock Price Forecast$75.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+841.0%Consensus RatingBuy Rating Score (0-4)3 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,160,000.00 Net Margins-34.03% Pretax Margin-33.98% Return on Equity-62.40% Return on Assets-30.27% Debt Debt-to-Equity Ratio0.66 Current Ratio3.34 Quick Ratio2.22 Sales & Book Value Annual Sales$39.19 million Price / Sales0.70 Cash FlowN/A Price / Cash FlowN/A Book Value$4.11 per share Price / Book1.07Miscellaneous Outstanding Shares6,180,000Free Float6,046,000Market Cap$27.25 million OptionableNot Optionable Beta1.55 BIOLASE Frequently Asked Questions Should I buy or sell BIOLASE stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BIOLASE stock. View analyst ratings for BIOLASE or view top-rated stocks. What is BIOLASE's stock price forecast for 2022? 4 equities research analysts have issued 12 month target prices for BIOLASE's stock. Their BIOL stock forecasts range from $12.00 to $75.00. On average, they predict BIOLASE's stock price to reach $41.50 in the next year. This suggests a possible upside of 841.0% from the stock's current price. View analysts' price targets for BIOLASE or view top-rated stocks among Wall Street analysts. How has BIOLASE's stock price performed in 2022? BIOLASE's stock was trading at $9.75 at the beginning of 2022. Since then, BIOL stock has decreased by 54.8% and is now trading at $4.41. View the best growth stocks for 2022 here. When is BIOLASE's next earnings date? BIOLASE is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for BIOLASE. How were BIOLASE's earnings last quarter? BIOLASE, Inc. (NASDAQ:BIOL) issued its quarterly earnings data on Thursday, May, 12th. The medical technology company reported ($0.81) earnings per share for the quarter. The medical technology company earned $10.17 million during the quarter. BIOLASE had a negative trailing twelve-month return on equity of 62.40% and a negative net margin of 34.03%. View BIOLASE's earnings history. When did BIOLASE's stock split? How did BIOLASE's stock split work? Shares of BIOLASE reverse split before market open on Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of BIOLASE stock prior to the reverse split would have 4 shares after the split. What guidance has BIOLASE issued on next quarter's earnings? BIOLASE issued an update on its second quarter 2022 earnings guidance on Thursday, June, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $10.50M-, compared to the consensus revenue estimate of $10.20 million. Who are BIOLASE's key executives? BIOLASE's management team includes the following people: Mr. John R. Beaver, Pres, CEO & Director (Age 61, Pay $876.18k)Ms. Jennifer Bright, VP of Fin.Mr. Richard R. Whipp, VP of Operations (Age 70)Mr. Matthew Wilson, VP of HRDr. Samuel B. Low, Chief Dental Officer and VP of Dental & Clinical AffairsMr. Michael C. Carroll, Corp. Sec. (Age 50)Mr. David Rodriguez, Director of Education & Events What is Todd Norbe's approval rating as BIOLASE's CEO? 8 employees have rated BIOLASE CEO Todd Norbe on Glassdoor.com. Todd Norbe has an approval rating of 13% among BIOLASE's employees. This puts Todd Norbe in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of BIOLASE's key competitors? Some companies that are related to BIOLASE include Item 9 Labs (INLB), Sonendo (SONX), American Medical Technologies (ADLI), Lancer Orthodontics (LANZ) and Remedent (REMI). View all of BIOL's competitors. What other stocks do shareholders of BIOLASE own? Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Biocept (BIOC), Magnachip Semiconductor (MX), Fluidigm (FLDM), Matinas BioPharma (MTNB), MicroVision (MVIS), Acasti Pharma (ACST), Bionano Genomics (BNGO) and Genius Brands International (GNUS). What is BIOLASE's stock symbol? BIOLASE trades on the NASDAQ under the ticker symbol "BIOL." How do I buy shares of BIOLASE? Shares of BIOL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BIOLASE's stock price today? One share of BIOL stock can currently be purchased for approximately $4.41. How much money does BIOLASE make? BIOLASE (NASDAQ:BIOL) has a market capitalization of $27.25 million and generates $39.19 million in revenue each year. The medical technology company earns $-16,160,000.00 in net income (profit) each year or ($2.06) on an earnings per share basis. How many employees does BIOLASE have? BIOLASE employs 158 workers across the globe. How can I contact BIOLASE? BIOLASE's mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The official website for BIOLASE is www.biolase.com. The medical technology company can be reached via phone at (949) 361-1200, via email at rcaron@dresnerallencaron.com, or via fax at 949-273-6677. This page (NASDAQ:BIOL) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here